And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is quite modest this time around. We plan to catch up on some reading, hang with our short person, and take a few naps. And what about you? Given the to-do over taxes in Washington, you could run some numbers and see how your fortunes play out — will you be a winner or loser? You could also calculate how your cable bill might change if certain regulators dispense with a certain rule. Or you could simply shrug your shoulders and take a long walk in the park. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …

Amazon (AMZN) has held preliminary talks with generic drug makers about its potential entry into the pharmacy business, according to CNBC, citing an investor note by Leerink analysts. The conversations, with Mylan and the Sandoz unit of Novartis (NVS), have been described as high level, but the nature of Amazon’s plans is not yet clear. One of the people said the talks are about Amazon taking a role in drug purchasing.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy